Pressure BioSciences Inc (OTCMKTS:PBIO) announced Thursday the official opening of its new Ultra Shear Technology Demonstration Laboratory at the company's South Easton, Massachusetts facility.
A major purpose of the UST Demo Lab is to showcase the ability of the company's revolutionary UST Platform to process CBD oil into true, high quality, water-soluble nanoemulsions, according to a statement.
It is expected that nanoemulsions of CBD will be more stable, have superior aesthetic quality, and offer higher bioavailability than the standard macro/microemulsions used in most CBD products today, the company said.
A second purpose of the lab is to invite potential purchasers of the company's UST-based BaroShear Systems -- the initial release is expected in the fourth quarter of 2020 -- to evaluate how their CBD and other product formulations work with the company's UST platform.
CBD and other cannabinoids are extracted from the hemp plant in an oil form. The water-based biology of human bodies has difficulty accessing and absorbing oily molecules from ingested or topically applied hemp oil drops.
Kenneth Micciche, director of PBI's UST Program, said the company processed samples of CBD oil formulations from several highly interested companies over the past two months in an effort to optimize the service announced Thursday.
He said Vegas CBD Factory ordered six BaroShear K45 systems for delivery and installation in 4Q of 2020.
"My colleagues in the cannabis market are beginning to realize that high-quality CBD products will only come by using high quality, water-soluble nanoemulsions of CBD oil, such as those generated from processing CBD Oil with PBI's UST platform, which I have observed first-hand in their lab," said Jason Ellis, president of Vegas CBD Factory.
More purchase orders
Micciche said several more companies that participated in the early evaluation process are close to giving the company their purchase orders.
“The ability to showcase the UST platform in real life, and see the final product first-hand, has been shown to be vital to our marketing efforts. As has been said in the past: 'build it and they will come'. The opening of the UST Demo Lab is a critical accomplishment in our UST sales and marketing strategy," he added.
Pressure Biosciences CEO Richard Schumacher commented: "The initial reactions from manufacturers of topical and ingestible cannabidiol products processed in our lab during the trial period have been extremely positive. They quickly saw how they could realize substantial cost reductions while eliminating the overloading of poorly water-soluble CBD and other cannabinoids into products to achieve targeted dosing levels.
“We believe our breakthrough technology platform provides them with a new-found ability to provide safe and effective dosing for their customers, which in turn should stimulate greater growth in the market for CBD-based products overall, and strong sales of our BaroShear product line when it is released to the market later this year."
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham